Motorola Solutions, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Motorola Solutions, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.96B | Feb 16, 2018 |
| FY2017 | Sep 30, 2017 | $1.65B | Feb 16, 2018 |
| FY2017 | Jul 1, 2017 | $1.50B | Feb 16, 2018 |
| FY2017 | Apr 1, 2017 | $1.28B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $1.88B | Feb 16, 2018 |
| FY2017 | Oct 1, 2016 | $1.53B | Feb 16, 2018 |
| FY2017 | Jul 2, 2016 | $1.43B | Feb 16, 2018 |
| FY2017 | Apr 2, 2016 | $1.19B | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.68B | Feb 21, 2017 |
| FY2016 | Oct 3, 2015 | $1.42B | Feb 21, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.68B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.82B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $9.98B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $9.11B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $8.17B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $2.27B | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | $1.87B | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | $1.62B | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | $1.66B | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $2.38B | Feb 12, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.04B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.51B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $4.97B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $4.23B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $4.04B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $1.15B | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | $909.00M | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | $766.00M | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | $787.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $1.22B | Feb 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.71B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.36B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.25B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $412.00M | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | $205.00M | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | $135.00M | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | $197.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $244.00M | Feb 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.69B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.29B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.66B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.67B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $555.00M | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | $352.00M | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | $218.00M | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | $259.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $590.00M | Feb 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $970.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $917.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $858.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $779.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $734.00M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $182.00M | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | $175.00M | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | $161.00M | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | $168.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $182.00M | Feb 12, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.87B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.75B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.56B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.45B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.35B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $343.00M | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | $313.00M | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | $297.00M | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | $341.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $368.00M | Feb 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.39B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.04B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.82B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.84B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.61B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.82B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.08B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.35B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.17B | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.39B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $14.60B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $13.34B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $12.81B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $12.19B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $10.88B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $10.64B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $9.41B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $8.21B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $8.46B | Feb 15, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.41B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $724.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $116.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($40.00M) | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | ($558.00M) | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | ($700.00M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($1.29B) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($1.74B) | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | ($964.00M) | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.80B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.53B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.40B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.31B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.57B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.22B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $2.07B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.51B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $938.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $728.00M | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.30B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.64B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.34B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.35B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.13B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.24B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.05B | Feb 14, 2020 |
| FY2018 | Jan 1, 2018 | $594.00M | Feb 15, 2019 |
| FY2018 | Dec 31, 2017 | $467.00M | Feb 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.10B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.71B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.33B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.87B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.25B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.00B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.26B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.21B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $967.00M | Feb 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $1.50B | Feb 15, 2012 |
| FY2010 | Dec 31, 2010 | $2.80B | Feb 18, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 10 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 8 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 12, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 12, 2021 |
| FY2020 | Sep 26, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 28, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 12, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 165.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 167.10M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 166.20M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 167.50M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 168.70M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 169.40M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | 170.50M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | 163.50M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | 161.20M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 164.70M | Feb 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $728.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $654.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $589.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $530.00M | Feb 14, 2025 |
| FY2022 | Jan 14, 2022 | $148.00M | Feb 16, 2023 |
| FY2023 | Dec 31, 2021 | $482.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $436.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $379.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $337.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $307.00M | Feb 14, 2020 |